A Phase II Multicenter Study to Assess the Feasibility and Efficacy of the Addition of an Interphase Cycle With Flotetuzumab Prior to Start Conditioning for an Allogeneic HCT in AML With MRD After 2 Cycles of Intensive Chemotherapy
Latest Information Update: 26 Dec 2022
At a glance
- Drugs Flotetuzumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms HOVON162AML
- 20 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Oct 2021 New trial record